Evidence map›Paper›PMID 39601172›Full record

ArticleProtein and peptide letters2025

Recombinant Production of Ib-AMP

Majid Safari, Hamid Abtahi, Shima Chehreii, Shohreh Fahimirad

Abstract read
PubMed Publisher
In one paragraph

Article in Protein and peptide letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Majid SafariDepartment of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Arak, Iran.
Hamid AbtahiMolecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Shima ChehreiiDepartment of Microbiology, Faculty of Basic Sciences, Islamic Azad University, Arak, Iran.
Shohreh FahimiradMolecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethicillin-resistant

objectivesThis study aimed to produce recombinant versions of Ib-AMP

methods

resultsThe individual antimicrobial activities of Ib-AMP

conclusionAntimicrobial peptides (AMPs) have attracted significant interest owing to the growing intricacy of microbial infections. They constitute a promising category of novel antibiotics that warrant further investigation for the treatment of

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesMethicillin-Resistant Staphylococcus aureusDrug SynergismEscherichia coliMicrobial Sensitivity TestsRecombinant ProteinsAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesRecombinant Proteinsantimicrobial peptideEscherichia coliIb-AMP4minimum inhibitory concentrations (MICs).Oncorhyncin IIStaphylococcus aureus

Identifiers

PMID39601172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.